Levofloxacin Krka (Levofloxacin)

Levofloxacin exerts its antibacterial effect by inhibiting two essential enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are required for DNA supercoiling and replication. By binding to them, levofloxacin prevents bacterial DNA synthesis and transcription, leading to rapid bacterial cell death.

The specific dose of Levofloxacin Krka is determined by the prescribing clinician based on the infection type, severity, patient age, renal function, and local resistance patterns. Healthcare professionals should follow current clinical guidelines and the product label when selecting the appropriate regimen.

Safety data for levofloxacin in pregnancy are limited, and the drug is generally avoided unless the potential benefit outweighs the risk to the fetus. It is also excreted in breast milk, so breastfeeding mothers should discuss alternatives with their healthcare provider. Consultation with a specialist is recommended.

To request Levofloxacin Krka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levofloxacin offers a broader spectrum of activity against Gram‑positive organisms compared with ciprofloxacin, while both share similar activity against many Gram‑negative pathogens. Levofloxacin is often dosed once daily, which can improve adherence, whereas ciprofloxacin typically requires twice‑daily dosing. Both share class‑related safety considerations, so selection depends on infection site, susceptibility, and patient factors.

Levofloxacin Krka should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in areas of high humidity or near heat sources. Keep the product out of reach of children.

Levofloxacin Krka is administered orally, usually with a full glass of water. It can be taken with or without food, but patients should avoid taking it simultaneously with antacids or mineral supplements that contain calcium, magnesium, aluminum, or iron, as these can impair absorption.

The most serious risks include tendon rupture or tendinitis, especially in older adults or those on corticosteroids; QT interval prolongation leading to cardiac arrhythmias; Clostridioides difficile‑associated colitis; severe allergic reactions such as anaphylaxis; peripheral neuropathy; and hepatic dysfunction. Patients should be educated to report any sudden joint pain, palpitations, severe diarrhea, or rash promptly.

Levofloxacin Krka should be avoided in individuals with a known hypersensitivity to levofloxacin or other fluoroquinolones, patients with a history of tendon disorders related to fluoroquinolone use, and those taking concomitant medications that significantly increase the risk of tendon injury. Caution is also advised for patients with uncontrolled epilepsy, myasthenia gravis, or severe renal impairment, and it is generally not recommended for pregnant or nursing women unless absolutely necessary.